Drug intelligence / Profile preview

ImmuniStim

Development stage: Unknown
Lead developer: TC BioPharm
Modality: Cell Therapies

Overview

**ImmuniStim** is an unmodified allogeneic gamma delta T (GD-T) cell therapy developed by TC BioPharm for treating COVID-19. It leverages the innate immune properties of gamma delta T cells to provide rapid antiviral activity and immune modulation without genetic modification. Administered as an off-the-shelf cellular immunotherapy, it aims to combat viral infections by harnessing GD-T cells' ability to target infected cells and stimulate broader immune responses.[6]

Brand names: ImmuniStim

Beyond the preview

Go deeper on ImmuniStim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuniStim.

Explore the full profile